IQVIA Holdings Inc. $IQV Shares Bought by WCG Wealth Advisors LLC

WCG Wealth Advisors LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 103.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,582 shares of the medical research company’s stock after purchasing an additional 17,047 shares during the period. WCG Wealth Advisors LLC’s holdings in IQVIA were worth $7,570,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Geode Capital Management LLC raised its position in IQVIA by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of IQVIA by 1.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after acquiring an additional 41,643 shares in the last quarter. Boston Partners acquired a new stake in shares of IQVIA during the 3rd quarter worth about $676,698,000. Finally, Artisan Partners Limited Partnership raised its position in shares of IQVIA by 4.9% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,433,957 shares of the medical research company’s stock worth $652,246,000 after acquiring an additional 161,085 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Up 0.8%

IQV opened at $182.12 on Thursday. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The business has a 50 day simple moving average of $171.35 and a 200-day simple moving average of $195.26. The stock has a market capitalization of $30.40 billion, a P/E ratio of 22.57, a P/E/G ratio of 1.73 and a beta of 1.21. IQVIA Holdings Inc. has a 12 month low of $143.00 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period last year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.58 earnings per share for the current fiscal year.

IQVIA announced that its board has initiated a share buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its shares are undervalued.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Truist Financial dropped their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Evercore reiterated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research note on Wednesday, April 8th. Citigroup lowered their target price on IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 price target on IQVIA in a report on Friday, February 6th. Finally, Mizuho set a $215.00 price target on IQVIA in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.